Hartman found that Rapamycin enhanced cilia formation in TSC1 and TSC2 null cells and concluded that the efficacy of mTOR inhibitors on renal cystic disease in patients carrying a TSC mutation or PKD1/TSC2-CGS may differ from its efficacy in ADPKD [40]. The gene discussed is MTOR; the disease is autosomal dominant polycystic kidney disease.